Vasopeptidase Inhibitors

A class of cardiovascular drugs indicated for hypertension and congestive heart failure that simultaneously inhibit both NEUTRAL ENDOPEPTIDASE and ANGIOTENSIN CONVERTING ENZYME. They increase the availability of NATRIURETIC PEPTIDES and BRADYKININ and inhibit production of ANGIOTENSIN II.

Also Known As:

ACE-NEP Inhibitors; NEP-ACE Inhibitors; ACE NEP Inhibitors; Inhibitor, Vasopeptidase; NEP ACE Inhibitors; Vasopeptidase Inhibitor

Networked: 106 relevant articles (15 outcomes, 27 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Enzyme Inhibitors: 1659
      - Protease Inhibitors: 6291
        Angiotensin-Converting Enzyme Inhibitors: 17791
        Vasopeptidase Inhibitors: 106

Experts

1.	Adam, Albert: 7 articles (10/2005 - 01/2002)
2.	Lapointe, Nathalie: 6 articles (10/2005 - 01/2002)
3.	Quaschning, Thomas: 5 articles (01/2006 - 11/2001)
4.	Rouleau, Jean-Lucien: 5 articles (10/2005 - 01/2002)
5.	Rouleau, J L: 4 articles (10/2001 - 08/2000)
6.	Yorek, Mark A: 3 articles (12/2012 - 01/2008)
7.	Parker, Thomas G: 3 articles (10/2005 - 12/2003)
8.	Blais, Charles: 3 articles (12/2003 - 01/2002)
9.	Clément, Robert: 3 articles (12/2003 - 01/2002)
10.	Rouleau, Jean L: 3 articles (12/2003 - 05/2002)

Related Diseases

1.	Heart Failure 01/01/2001 - "Preliminary clinical trials in heart failure with vasopeptidase inhibitors have become available and show promising results. " 06/01/2002 - "Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. " 12/01/2003 - "The results suggest that vasopeptidase inhibitor suppressed cardiac remodeling in the setting of chronic heart failure, possibly acting through the direct inhibition of cardiac NEP. " 08/01/2003 - "Vasopeptidase inhibitors for heart failure: where do we go from here?" 09/01/2002 - "Vasopeptidase inhibitors in heart failure."
2.	Hypertension (High Blood Pressure) 01/01/2005 - "Based on these considerations, numerous preclinicial studies with vasopeptidase inhibitors were performed and revealed promising results in experimental hypertension. " 02/01/2002 - "Based on these considerations, numerous preclinical studies with vasopeptidase inhibitors have been performed and reveal promising results in experimental hypertension. " 01/01/2002 - "Simultaneous inhibition NEP and ACE by a single molecule (a vasopeptidase inhibitor) is a new therapeutic approach in hypertension. " 01/01/2020 - "This new information will be very useful in the design of safer and more selective vasopeptidase inhibitors of NEP and ACE for effective treatment in hypertension and heart failure." 08/01/2002 - "Whereas vasopeptidase inhibitors have demonstrated clinical efficacy in hypertension and heart failure, their effects in myocardial ischaemia remain unclear. "
3.	Type 2 Diabetes Mellitus (MODY) 03/01/2009 - "Thus, vasopeptidase inhibitors may be an effective treatment for diabetic microvascular and neural complication in type 2 diabetes." 02/29/2012 - "Treating high fat fed/low dose streptozotocin-diabetic rats; model of type 2 diabetes, with ilepatril (vasopeptidase inhibitor, blocks neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE)) improved vascular and neural functions. " 06/01/2006 - "CGS 35601 is a triple vasopeptidase inhibitor (VPI) of angiotensin converting enzyme (ACE), neutral endopeptidase (NEP), and endothelin (ET) converting enzyme-1 (ECE-1), with respective IC(50) values of 22, 2, and 55 nM. The aim of the present study was to establish the hemodynamic profile of Zucker diabetic fatty (Zdf)-Fatty rats, a high-fat diet gene-prone model developing spontaneous Type 2 diabetes (T2D) and the effects of CGS 35601. "
4.	Chronic Renal Insufficiency 01/01/2012 - "The activation of the KKS by angiotensin I-converting enzyme inhibitors and vasopeptidase inhibitors is likely to be beneficial in senescence-associated cardiovascular diseases and chronic kidney diseases." 12/15/2005 - "CURRENT AND FUTURE NEPHRO-PROTECTION IN HUMANS: The same model serves for evaluation of new organo-protective therapies such as vasopeptidase inhibitors, blockade of endothelin, chemokine and collagen receptors as well as stem cell therapy and their potential benefit for patients with chronic renal diseases."
5.	Diabetic Nephropathies (Diabetic Nephropathy) 01/01/2004 - "The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy." 01/01/2002 - "Wider applications for vasopeptidase inhibitors being studied include their role as cardioprotective agents in heart failure, as renoprotective agents in chronic renal failure and diabetic nephropathy, and as vasculoprotective agents in endothelial dysfunction and athersclerosis." 01/01/2007 - "A collection of recent studies has shown that angiotensin-converting enzyme inhibitors, which inhibit angiotensin II formation and degradation of bradykinin, and vasopeptidase inhibitors attenuated the development of diabetic nephropathy in experimental animals and clinical settings. " 01/01/2004 - "We tested the effects of the dual inhibition of both angiotensin converting enzyme and neutral endopeptidase by the vasopeptidase inhibitor AVE7688 in an animal model of Type 2 diabetic nephropathy. "

Related Drugs and Biologics

1.	omapatrilat
2.	AVE 7688
3.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
4.	Neprilysin (Neutral Endopeptidase)
5.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
6.	Endothelins (Endothelin)
7.	Streptozocin (Streptozotocin)
8.	Collagen Receptors
9.	Chemokines
10.	Salts

Related Therapies and Procedures

1.	Therapeutics
2.	Surgical Instruments (Clip)
3.	Catheters
4.	Nephrectomy
5.	Ligation